EBV Antibodies in Egyptian Patients with Multiple Sclerosis
A study was planned to evaluate the frequency and levels of EBV-specific antibodies in Egyptian patients with multiple sclerosis, comparing them to healthy controls. The primary endpoints include the percentages of participants with specific antibody seropositivity.
- Tags
- #Other
- Most relevant to
- —
- Source
- Read original source
Why it matters
Understanding the relationship between EBV antibodies and MS could provide insights into the disease's mechanisms and potential links to EBV infection, offering future avenues for research and understanding disease activity.
What this does not prove
The study has not started recruiting, and no results are available yet. There are no findings to report as the endpoints remain unachieved at this time.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Yes
- Primary endpoint met
- Not reported
- Relevant MS type
- All
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Other
Original sources
Supporting passages (8)
subjects"studyPopulation": "The study population comprises adult Egyptian patients aged 18 to 55 years diagnosed with multiple sclerosis who attend the Department of Neurology and Psychiatry at Assiut University Hospital (Assiut, Egypt), along with age- and sex-matched apparently healthy control individuals recruited from the same geographic region.",
controlled"observationalModel": "CASE_CONTROL",
research categoriesHowever, the serological profile, antibody titers, and clinical relevance of EBV infection among Egyptian individuals with MS remain limited.\n\nThe primary purpose of this hospital-based observational study is to evaluate the frequency and titers of EBV-specific antibodies, specifically anti-viral capsid antigen (anti-VCA) IgG and anti-Epstein-Barr virus nuclear antigen 1 (anti-EBNA1) IgG, in Egyptian patients diagnosed with MS compared with age- and sex-matched healthy controls.
relevant ms types"studyPopulation": "The study population comprises adult Egyptian patients aged 18 to 55 years diagnosed with multiple sclerosis who attend the Department of Neurology and Psychiatry at Assiut University Hospital (Assiut, Egypt), along with age- and sex-matched apparently healthy control individuals recruited from the same geographic region.",
comparator"studyPopulation": "The study population comprises adult Egyptian patients aged 18 to 55 years diagnosed with multiple sclerosis who attend the Department of Neurology and Psychiatry at Assiut University Hospital (Assiut, Egypt), along with age- and sex-matched apparently healthy control individuals recruited from the same geographic region.",
primary endpoint"measure": "Percentage of Participants With Anti-EBNA1 IgG Seropositivity",
findingsHowever, the serological profile, antibody titers, and clinical relevance of EBV infection among Egyptian individuals with MS remain limited.\n\nThe primary purpose of this hospital-based observational study is to evaluate the frequency and titers of EBV-specific antibodies, specifically anti-viral capsid antigen (anti-VCA) IgG and anti-Epstein-Barr virus nuclear antigen 1 (anti-EBNA1) IgG, in Egyptian patients diagnosed with MS compared with age- and sex-matched healthy controls.
limitationsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.